Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
AUSTIN, Texas, Oct. 31, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 14, 2013, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2013. Financial results will be issued in a press release prior to the call.
Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period.
Date: Thursday, November 14, 2013
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-800-734-8507
International dial-in number: 1-212- 231-2918
Conference ID: 21676489
The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call through November 28, 2013.
Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21676489
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Liolios Group, Inc.
SOURCE Vermillion, Inc.
More by this Source
Vermillion Reports Fourth Quarter and Full Year 2013 Results
Mar 06, 2014, 16:01 ET
Vermillion to Present at the 26th Annual ROTH Conference on March 11, 2014
Mar 03, 2014, 16:01 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.